Clinical trials: Tolerability
Chronic Hepatitis b
A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics.
- Trial name
- NCT06085053
- Testing
- TQA3038 injection
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Healthy Volunteer
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
- Trial name
- NCT07219030
- Testing
- Emraclidine
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically…
- Trial name
- NCT05985200
- Testing
- BI 3032950
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2…
- Trial name
- NCT07765511
- Testing
- Macupatide, Eloralintide
- Where
- 3 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Subjects
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be…
- Trial name
- MAD (NCT03866369)
- Testing
- Moxifloxacin, Lanifibranor
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Inventiva Pharma
Lichen Simplex Chronicus
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07619183
- Testing
- PG-033 tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
- Trial name
- NCT06132841
- Testing
- AZD6234
- Where
- 3 sites in United States, Japan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subject
Single-dose PK Study of Benapenem In Healthy Subjects
To design 11 dose groups within 62.5 mg ~ 4000 mg for single-dose tolerability study. A single-center, randomized, blinded, placebo-controlled, dose escalation trial design is adopted.
- Trial name
- NCT03588156
- Testing
- Benapenem
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Schizophrenia
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study
- Trial name
- NCT06105151
- Testing
- VV119(SAD), VV119(FE)
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Healthy
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551
The purpose of this study is to determine how well tolerated and safe AZD2551 is at different dose levels in healthy, non-smoking males. It will also investigate how quickly AZD2551 is absorbed into and cleared by the body
- Trial name
- NCT00860353
- Testing
- AZD2551
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Tetanus
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human…
- Trial name
- NCT06939777
- Testing
- SNA02-48, HTIG, Tetanus Toxoid
- Where
- China
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Healthy
Compare Bioavailability of RO7239361 After Subcutaneous Injection
Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.
- Trial name
- NCT03100630
- Testing
- RO7239361
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Thrombosis
The PK/PD Study of SHR2285 Tablets in Healthy Subjects
Thrombosis is a maladaptive process of vascular occlusion and remains a primary cause of cardiovascular morbidity and mortality, The dose-limiting issue with available anticoagulant therapies is bleeding.
- Trial name
- NCT03769831
- Testing
- SHR2285
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
First in Human Study for PF-06667272
The current study is the first clinical trial proposed with PF-06667272. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of PF-06667272 under fed and fasted conditions, in…
- Trial name
- NCT03126149
- Testing
- PF-06667272
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza Prophylaxis
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01863849
- Testing
- Vaccination with Fluval AB suspension for injection
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Healthy
A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.
- Trial name
- NCT03990519
- Testing
- JNJ-26366821
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Safety, Blood Levels and Effects of MGB-BP-3
This study is to assess the safety and tolerability aspects of oral MGB-BP-3, a treatment for Clostridium difficile infections.
- Trial name
- NCT02518607
- Testing
- MGB-BP-3
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MGB Biopharma Limited
Dry Skin, Sensitive Skin
A Clinical Study to Assess the Safety, In-use Tolerability of Test Product in Healthy Adult Subjects With Dry and Sensitive Skin.
This is open-label, interventional, prospective, safety in-use tolerability study of test product "No Rays, Thanks Mineral Sunscreen" in healthy adult human subjects with dry and sensitive skin.
- Trial name
- NCT06489600
- Testing
- No Rays, Thanks Mineral sunscreen
- Where
- India
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- NovoBliss Research Pvt Ltd
Pulmonary Disease, Chronic Obstructive
QTc Study GSK573719+GW642444
This is a randomized, placebo controlled, four period incomplete block,crossover thorough QT study to estimate the effect of repeat dose GSK573719/GW642444M (Vilanterol) combination and GSK573719 monotherapy on the QTc interval…
- Trial name
- NCT01521377
- Testing
- Moxifloxacin, GSK573719/Vilanterol 125/25mcg, GSK573719
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Chinese healthy male participants: the safety of BAY1747846 when given at increasing single doses…
- Trial name
- NCT06135181
- Testing
- Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg, Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.